drugset / Trial / NCT05177042
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1b study to assess the combination of ARV-110 (bavdegalutamide) and abiraterone in participants with metastatic prostate cancer with rising PSA values on abiraterone.
Timeline
- Start
- 2022-05-13
- Primary completion
- 2024-07-02
- Completion
- 2025-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavdegalutamide | Small molecule | 420 mg | Oral |
| Background | Abiraterone acetate | Small molecule | — | Oral |